A recent survey reveals that approximately three million Canadian adults are currently taking GLP-1 drugs, such as Ozempic or Mounjaro. The survey also indicates that many more Canadians would like to use these medications, but cost is a significant barrier. The poll, conducted by Leger Healthcare, highlights the impact of GLP-1 drugs on users' eating habits and spending behavior. Over half of the surveyed individuals reported a decreased appetite, and 40% mentioned reduced food cravings. Consequently, about 30% of GLP-1 users are dining out or ordering takeout less frequently. Interestingly, a third of the surveyed users are purchasing more fresh fruits, vegetables, and protein-rich foods. Weight loss is the primary reason for taking or considering GLP-1 medications, followed by diabetes management. The survey also reveals that 8% of respondents are currently taking prescription GLP-1 medications, which translates to approximately three million Canadian adults. Similarly, 6% of respondents expressed interest in taking GLP-1 medications, equating to more than two million Canadian adults. GLP-1 usage is even more prevalent in the United States, with 11% of surveyed Americans reporting medication use. Americans are twice as likely as Canadians to want to take GLP-1 medications, with 12% expressing interest. Cost and insurance coverage significantly influence Canadians' decisions to take GLP-1 medications. More than half of those interested in taking the medication in Canada mentioned that having insurance coverage or lower-cost generic options would impact their decision. Leger Healthcare's research emphasizes that GLP-1s are no longer a niche health topic but a mainstream consumer and healthcare trend. The survey's findings indicate that the impact of GLP-1s is evident in shopping habits and behaviors, not just prescriptions. In addition to dining out less, about 35% of GLP-1 users reported ordering smaller portions, choosing lighter or healthier options, and not finishing their meals. Furthermore, 36% of users have reduced their alcohol consumption. GLP-1 usage is also transforming purchasing habits outside the grocery store, with increased spending on clothes, personal care products, beauty services, and fitness. The survey estimates that approximately two million Canadian adults are not taking GLP-1 medications but would like to. While cost and lack of insurance coverage are barriers for about half of the respondents interested in taking GLP-1s, another 36% would consider the medication if the risk of side effects was lower. Common gastrointestinal side effects include nausea, vomiting, constipation, and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, according to doctors. Weight loss is the main driver for 58% of people taking or considering GLP-1 drugs, while 42% cited diabetes management. Heart health is a reason for 22% of respondents, with men more likely to mention this compared to women. The survey reveals that a quarter of the respondents taking GLP-1 medications are paying for the drugs out of pocket, which can cost hundreds of dollars a month. Insurance coverage varies, with 28% fully covered by private or public plans, and almost half having partial insurance coverage. Leger Healthcare conducted the online survey with 1,536 Canadians and 1,012 Americans aged 18 and over from February 6 to 9, 2026. The polling industry's professional body, the Canadian Research Insights Council, notes that online surveys do not have a margin of error due to non-random sampling. This report by The Canadian Press was first published on March 3, 2026, and is supported by a partnership with the Canadian Medical Association.
